» Articles » PMID: 32104189

Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis

Overview
Date 2020 Feb 28
PMID 32104189
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the efficacy and safety of traditional Chinese medicine (TCM) on lung function and quality of life of idiopathic pulmonary fibrosis (IPF) patients by meta-analysis.

Methods: Randomized controlled trials (RCTs) related to TCM and IPF were searched on PubMed, EMBASE Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chin VIP Information (VIP), and Chinese Biomedical Database (CBM) until December 2018. Standard mean difference (SMD) and 95% CI were calculated for the measurements related to lung function (FEV1/FVC, FVC%, FEV1%, TLC%, DLCO% or DLCO, and VC%) and other parameters (PO2, 6MWD, and SGRQ) when comparing TCM treatment to the control group. Relative risk (RR) and 95% CI of adverse events (AEs) were calculated to assess the safety of TCM.

Results: A total of 40 RCTs comparing TCM to western medicine (WM) and involving 3194 IPF patients were eligible for the meta-analysis. The pooled results showed that TCM treatment improved significantly PO2 (SMD = 0.80, 95% CI 0.54 to 1.06, p < 0.001), FEV1% (SMD = 0.57, 95% CI 0.42 to 0.71, p < 0.001), DLCO% (SMD = 0.38, 95% CI 0.28 to 0.48, p < 0.001), 6MWD (SMD = 0.70, 95% CI 0.56 to 0.84, p < 0.001) and other measurements and reduced SGRQ scores (SMD = −0.51, 95% CI −0.70 to −0.22, p < 0.001). Subgroup analysis of different study durations (3 months, ≥ 6 months) and comparison models (TCM vs. WM, TCM + WM vs. WM or TCM vs. placebo) showed similar results. No significant difference of risk of AEs was observed between both groups (RR = 0.66, 95% CI: 0.27–1.60, p=0.352). There was no obvious publication bias, and the pooled results were stable according to sensitivity analysis.

Conclusion: To the best of our knowledge, the present study had the largest sample size. Our results indicated that TCM treatment may help provide benefit to the lung function, exercise capacity, and quality of life of IPF patients, alone or combined with WM, when compared to WM. More rigorous RCTs were needed in the future.

Citing Articles

Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.

Yang S, Yu X, Li J, Xie Y, Zhang W, Ban C Trials. 2022; 23(1):725.

PMID: 36056382 PMC: 9438282. DOI: 10.1186/s13063-022-06684-0.


Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats.

Du Q, Wu X, An L, Zhou R, Xiao X, Wu C Evid Based Complement Alternat Med. 2022; 2022:4933255.

PMID: 35733628 PMC: 9208943. DOI: 10.1155/2022/4933255.


Danggui Buxue Decoction Ameliorates Idiopathic Pulmonary Fibrosis through MicroRNA and Messenger RNA Regulatory Network.

Zhang H, Wang X, Shi Y, Liu M, Xia Q, Jiang W Evid Based Complement Alternat Med. 2022; 2022:3439656.

PMID: 35518349 PMC: 9064538. DOI: 10.1155/2022/3439656.


Study on the Mechanism of Astragalus Polysaccharide in Treating Pulmonary Fibrosis Based on "Drug-Target-Pathway" Network.

Bing P, Zhou W, Tan S Front Pharmacol. 2022; 13:865065.

PMID: 35370663 PMC: 8964346. DOI: 10.3389/fphar.2022.865065.


Efficacy and Safety of Dahuang Zhechong Pill in Silicosis: A Randomized Controlled Trial.

Tang W, Liang J, Wu J, Liu L, Lu M, He X Evid Based Complement Alternat Med. 2021; 2021:4354054.

PMID: 34840587 PMC: 8616670. DOI: 10.1155/2021/4354054.


References
1.
Kistler K, Nalysnyk L, Rotella P, Esser D . Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014; 14:139. PMC: 4151866. DOI: 10.1186/1471-2466-14-139. View

2.
King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

3.
Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

4.
Ley B, Collard H, King Jr T . Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 183(4):431-40. DOI: 10.1164/rccm.201006-0894CI. View

5.
Noth I, Anstrom K, Calvert S, De Andrade J, Flaherty K, Glazer C . A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186(1):88-95. PMC: 3400994. DOI: 10.1164/rccm.201202-0314OC. View